A Phase II Trial of Cetuximab (C225) as Therapy for Recurrent Non-Small Cell Lung Cancer (NSCLC)
To determine the tumor response rate and time to disease progression, survival and safety in
the EGFR-positive, EGFR-negative and total populations.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective of this study was to determine the tumor response rate for single-agent cetuximab in EGFR+ subjects.
Every 8 weeks
No
E-mail: ClinicalTrials@ ImClone.com
Study Chair
ImClone LLC
United States: Food and Drug Administration
CA225-012
NCT00063388
May 2003
June 2005
Name | Location |
---|---|
ImClone Investigational Site | Indianapolis, Indiana 46202 |
ImClone Investigational Site | St. Charles, Missouri 63301 |
ImClone Investigational Site | Jacksonville, Florida 32207 |
ImClone Investigational Site | Decatur, Illinois 62526 |
ImClone Investigational Site | Boston, Massachusetts 02135 |